We Discover, Develop, and Deploy psychedelic inspired medicines to alleviate suffering and improve health.
MindMed is pioneering a new way to treat mental health problems. MindMed is working towards both non-hallucinogenic and hallucinogenic solutions:
Derived from psychedelics, zero to negligible hallucination effect
Pharmacy pickup, take-home
A dose of generic psychedelics which causes a hallucinogenic experience.
Direct supervision by therapist & doctor
In-clinic treatment only
NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NAS
We are creating transformative medicines to
address big problems in society.
A synthetic derivative of Ibogaine that is non-hallucinogenic and without the negative cardiac effects associated with Ibogaine.
18-MC is a synthetic congener of the naturally-occurring psychedelic compound ibogaine. Ibogaine is a Schedule 1 psychedelic and psychoactive substance that is extracted from the West Africa iboga shrub.
Historically, ibogaine has been used to treat opioid and other forms of substance addiction. While ibogaine is a mild stimulant in small doses, in larger doses it induces a profound psychedelic state.
Inspired by ibogaine’s apparent medicinal properties to treat addiction, MindMed’s scientific co-founder, Stanley Glick, PhD, MD, invented synthetic molecules that are related to ibogaine including 18-MC. 18-MC is designed to be non-hallucinogenic while retaining anti addictive properties.)
We are preparing the world’s first Phase II trial of microdosing LSD targeting Adult ADHD
MindMed plans to add additional microdosing trials of other forms of psychedelics with compelling therapeutic outcomes.
MindMed is actively acquiring or forming collaborations for new clinical trials of hallucinogenic doses of psychedelics.